A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson’s Disease (MAESTRO)

A Novel Trial of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson’s Disease (MAESTRO)
Cureus. 2022 Nov 23;14(11):e31818. doi: 10.7759/cureus.31818. eCollection 2022 Nov.ABSTRACTOveractive bladder (OAB) is experienced by more than half of patients with untreated Parkinson's disease. Treatment of overactive bladder in these patients has included antimuscarinic anticholinergics, raising concerns about the possibility of exacerbating cognitive impairment or constipation. Mirabegron (Myrbetriq), a β3-receptor agonist, provides relief of OAB without increasing cognitive impairment. While prior ... read more
Source: PubMedPublished on 2022-11-25By Arina Madan